More Media
Visit our Multimedia section to access more interesting videos as well as audio commentaries.
author profile
Cheryl Buxton
Global Managing Director of Client Services
Princeton
Cheryl Buxton is Korn/Ferry International's Global Managing Director of Client Services, based in the Firm’s Princeton office. In this role, she leads firm-wide client initiatives, including institutionalizing best practices in the Firm's go-to-market approach. Ms. Buxton is also the Sector Leader for Pharmaceuticals, part of the Firm's Global Life Sciences Market, and a member of Korn/Ferry's Global Operating Committee.
author profile
Ruchira Pathania
Senior Client Partner
Princeton
Ruchira Pathania is a Senior Client Partner in Korn/Ferry International’s Global Life Sciences Market, based in Princeton, NJ. She is also a member of the Firm’s Technology Centre of Expertise. For almost a decade, Ms. Pathania has focused on recruiting senior-level executives for Global 1000 and Fortune 500 pharmaceutical corporations, specialty pharmaceuticals, as well as start-up and venture funded companies in the Life Sciences sector.
See more
Can Big Pharma and Generics Executives Trade Places?
By
Cheryl Buxton and Ruchira Pathania
As the generics pharmaceuticals business model evolves, the industry faces many of the same challenges as those of the traditional big pharma. Consequently, generic drug companies may find that the key to continued growth will be breaking with tradition and recruiting and retaining seasoned big pharma executives. But, it cuts both ways, and big pharma may find that the expertise of generic drug executives accustomed to leaner budgets and product cycles is the tonic they need.
As the business evolves, what will successful leadership in the generics industry look like in the next five years? To learn more, the authors interviewed numerous executives at the world's largest top generics companies and found that while these executives are keen to point out critical differences in management and leadership styles, the business challenges are similar and professional crossover opportunities are immense.
Video
As the generics pharmaceuticals business model evolves, the industry faces many of the same challenges as those of the traditional big pharma. Consequently, generic drug companies may find that the key to continued growth will be breaking with tradition and recruiting and retaining seasoned big pharma executives. But, it cuts both ways, and big pharma may find that the expertise of generic drug executives accustomed to leaner budgets and product cycles is the tonic they need.
As the business evolves, what will successful leadership in the generics industry look like in the next five years? To learn more, the authors interviewed numerous executives at the world's largest top generics companies and found that while these executives are keen to point out critical differences in management and leadership styles, the business challenges are similar and professional crossover opportunities are immense.
View & Share
This publication is available for viewing. To send the publication to friends or colleagues, use the 'share' button.